Answers are grounded in this paper and cite their sources.
Peri-implant diseases such as peri-implant mucositis and peri-implantitis constitute a growing public health challenge, affecting approximately two-thirds of implant-carrying adults with (peri-implant mucositis) and approximately one in five (peri-implantitis), respectively, when defined by the 2017 World Workshop criteria. Conventional clinical and radiographic tools identify established tissue destruction rather than active biological disease, resulting in delayed intervention and irreversible bone loss. This mini review appraises current evidence on chairside diagnostic modalities for peri-implantitis and peri-implant mucositis, encompassing clinical probing parameters, radiographic assessment, peri-implant crevicular fluid (PICF) biomarker analysis, point-of-care (PoC) enzymatic tests, microbiological sampling, and emerging artificial intelligence (AI) augmented imaging. Among biomarker-based tools, the quantitative active-matrix metalloproteinase-8 (aMMP-8) lateral-flow immunotest (ImplantSafe®/ORALyzer®) demonstrates the strongest evidence base, achieving a sensitivity of 81.25% and specificity of 74.07% (AUC: 79.6%) and outperforming bleeding on probing as a marker of active collagen lysis. Cone-beam computed tomography (CBCT) offers superior three-dimensional defect characterization compared with periapical radiography, though metallic artifacts and radiation burden limit routine application. AI-assisted bone-loss grading on CBCT-derived sections achieved an overall accuracy, precision, recall, and F1-score of 0.90, representing a promising pathway toward automated implant monitoring. An integrated, multimodal chairside protocol that combines standardized clinical indices with point-of-care (PoC) biomarker analysis and selective radiographic imaging offers the most clinically realistic framework for early disease detection, treatment monitoring, and maintenance optimization. Limitations include heterogeneity of PICF sampling protocols, limited prospective validation of aMMP-8 diagnostic thresholds, and the need for large-scale AI validation across diverse patient populations.
No takes yet. Share an insight, caveat, or question.
Hoskeri et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: